Comparison Between Clonidine And Dexmedetomidine As Spinal Additive In Prolongation Of Postoperative Analgesia.

Intrathecal 0.75% Isobaric Ropivacaine versus 0.5% Hyperbaric Bupivacaine in transurethral resection of Prostate Surgery - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/089344

Enrollment

Registered

2025-06-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K400- Bilateral inguinal hernia, with obstruction, without gangrene

Interventions

Intervention1: 0.75% isobaric ropivacaine: Patients will be receiving 2.8ml of 0.75% Isobaric Ropivacaine (21mg). Total volume of the injected solution will be 2.8 ml. After skin infiltration with 2%

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 20-60yrs 2. ASA grade 1 & 2 3. Willing patients

Exclusion criteria

Exclusion criteria: 1. Uncooperative patients 2. Uncontrolled DM and SHTN 3. Allergy to study drugs 4. Height 5. Contraindication to spinal anaesthesia 6. Patient refusal 7. Infection at injection site 8. Increased intracranial pressure 9. Indeterminate neurological diseases 10. Coagulopathy

Design outcomes

Primary

Measure	Time frame
Our primary objective is to evaluate the efficacy of two different drugs of same group (alpha2 adrenergic agonist) clonidine & dexmedetimidine in combination with 0.5% hyperbaric bupivacaine via intrathecal route with regard to the quality of anaesthesia namely time to attain highest sensory and motor blockade, haemodynamic changes and time to first rescue analgesia.Timepoint: WITHIN 24 HOURS	—

Secondary

Measure	Time frame
sedatory effects of both drugs in the postoperative period.Timepoint: 5months	—

Countries

India

Contacts

Public ContactNantheta Ramu

SUDHA INSTITUTE OF MEDICAL SCIENCES

ronnienithi@gmail.com7397625589

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026